Intro

Join Professors Peter Nash and Philip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered a post hoc analysis examining the rapid and sustained efficacy of bimekizumab in PsA patients across different subgroups, focusing on improvements in pain, fatigue, and physical function over 16 weeks. The conversation also covered a long-term analysis of guselkumab assessing the durability of clinical improvements in joint and skin symptoms in PsA patients over a 2-year period.